Baseline Productions, Inc. Stock

BSSP

US0702491079

Biotechnology & Medical Research

Market Closed - OTC Markets 11:45:40 2022-08-02 EDT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		+9,900.00%	+9,900.00%

Current month	+9,900.00%
1 month	+9,900.00%

Press Releases: Baseline Productions, Inc.

21-06-30	Cantech Holdings, Inc. : Announces Completion of Required Documentation for Their Pink Sheet Current Listing With OTC Markets	PR
21-06-14	BASE PROD : Cantech Holding, Inc. Announces Update On Its Corporate Status And Intent To Become OTC Pink Sheet Current	PR

More press releases

Managers and Directors: Baseline Productions, Inc.

Manager	Title	Age	Since
Dennis Alexander CEO	Chief Executive Officer	-	-
Joanne Sylvanus DFI	Director of Finance/CFO	93	2015-10-31

Director	Title	Age	Since
Joanne Sylvanus BRD	Director/Board Member	93	2015-10-31
Dennis Alexander CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BASELINE PRODUCTIONS, INC.	-.--%	+9,900.00%	+9,900.00%	+9,900.00%	4.11K
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-6.23%	+26.01%	-2.99%	23.36B
Average	+4.10%	-0.38%	+1,037.37%	+1,136.54%	38.04B
Weighted average by Cap.	+3.23%	-0.29%	+48.19%	+161.47%

See all sector performances

Baseline Productions, Inc., formerly Cantech Holding, Inc., is a development-stage immunotherapeutic-based technology company. The Company is focused on commercialization of its proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsin Fraction (IPF) is a therapeutic platform technology that can be used to facilitate a range of applications. IPF turns on the immune system to fight autoimmune diseases. IPF binds to thymus (T)-cells and turns on T helper cell type 1 (Th1) immune system responses that kill infected cells. The Company's lead compound is a suspension of IPF, which is indicated for the treatment of autoimmune diseases, such as cancer, cirrhosis and Hepatitis C. The Company's product, IMMUNE-THERAPEUTIC PROTEIN (ITP), is a therapeutic protein isolated from porsine pepsin, which is irreversible, modified, and fractionate to the sequence IPF.

Employees

Sector

Biotechnology & Medical Research

More about the company